Identical quadruplets surprise mom expecting triplets

hqdefault

Kimberly and Craig Fugate were expecting Kenleigh, Kristen and Kayleigh. But Kelsey, born with her sisters on February 8, was a complete surprise.

The identical quadruplets were born via cesarean section in the Winfred L. Wiser Hospital for Women and Infants at the University of Mississippi Medical Center in Jackson, Mississippi.

“They had gotten the three out and they said, ‘More feet’. “I said, ‘No!’ It was an instant shock.”

The odds of spontaneous quadruplets — conceived without fertility assistance — are 1 in 729,000, according to Dr. James Bofill, Kimberly Fugate’s physician and a professor of maternal fetal medicine at the University of Mississippi.

The odds in this case were even slimmer as the Fugate girls are identical, meaning they split from a single egg.

“Those odds are incalculable,” Bofill said in a hospital press release. The last known set of identical quadruplets was born in Germany in January 2012. Experts estimate there are 50 to 60 sets worldwide.

You may know the Mathias quads — Grace, Emily, Mary Claire and Anna — who are in the eighth grade and appeared on the Discovery Health Channel’s “Super Quads.” And perhaps you remember a Lifetime reality show called “Four of a Kind,” which featured identical quadruplets Megan, Kendra, Sarah and Calli Durst, of Buffalo, Minnesota.

The Fugates were originally surprised to learn they were pregnant at all, according to WAPT. Then in November, the 42-year-old mom was told she was having triplets. The fourth baby managed to keep her existence a secret until Fugate went into labor at 28 weeks.

Kenleigh Rosa was born at 7:55, weighing 2 pounds, 1 ounce.

Kristen Sue was born at 7:57 weighing 2 pounds, 4 ounces.

Kayleigh Pearl was born at 7:58 weighing 2 pounds, 8 ounces.

And Kelsey Roxanne was born a minute later weighing 2 pounds, 6 ounces.

Bofill told The Clarion Ledger the hidden quad was a first in his 27-year career.

“I was very embarrassed, obviously,” Bofill said. “The news was sent to me by one of my fellows. I thought she was kidding.”

The quadruplets join older sister Katelyn, who is 10 years old. It’s unclear when they’ll be able to go home.

“Typically, when babies are born prematurely, doctors tell the families to expect them to stay in the (neonatal intensive care unit) until their original due date, which in this case would be May 2,” said hospital spokeswoman Jennifer Hospodor. “It is possible
that some or all of the girls would be stronger enough to go home before that, or have to stay longer. It depends on how they develop over the next 12 weeks.”

Source: CNN

 


Pill camera to screen for colon cancer approved in U.S.

An ingestible pill camera to help screen for polyps and early signs of colon cancer has been approved for use in the U.S.

Given Imaging Ltd.’s PillCam Colon was originally touted as an alternative to traditional colonoscopy procedures, but the company’s research found images taken by the mini-camera aren’t as clear as those taken during the more invasive procedure.

The U.S. Food and Drug Administration approved the device for patients who have experienced an incomplete colonoscopy. The company estimates 750,000 U.S. patients are not able to complete the procedure each year, due to anatomy issues, previous surgery or various colon diseases.

“Colonoscopy is the most comprehensive option, but for up to 10 per cent of individuals, achieving a complete colonoscopy may not be possible,” Eric Hargis, CEO of the Colon Cancer Alliance, said in a release.

In 2001, Given Imaging received FDA approval for a similar device that images the small intestine.

The newly approved capsule has two miniature colour video cameras, a battery and light source. Once the patient ingests the capsule, it is designed to transmit images for about 10 hours.

Data is transferred from the device to a computer to be compiled. A doctor later reviews and reports the results.

Risks of the procedure include capsule retention, aspiration and skin irritation. Before the capsule is excreted, patients should not be near powerful electromagnetic fields, such as those created by an MRI device.

The PillCam Colon is commercially available in Canada, Japan, Europe, Latin America, Australia and parts of Asia and Africa.

Given Imaging also develops technology to visualize, diagnose and monitor the digestive system, including with its PillCam, a swallowed capsule endoscope.

A report by the Canadian Partnership Against Cancer suggested that in 2011, half of Canadians aged 50 to 74 surveyed said they were up to date with their colorectal cancer screening — a fecal occult blood test in the past two years and colonoscopy in the past five years.

Last month, Alberta Health Services announced a new at-home, non-invasive screening test called “fit” – a fecal immunochemical test – for people aged of 50 to 74 at average risk of colorectal cancer.

A review of 19 studies published in Monday’s online issue of the Annals of Internal Medicine concluded FITs have high overall diagnostic accuracy for colorectal cancers.

Like the traditional fecal occult stool test, FIT involves collecting a stool sample at home to look for traces of blood. People using FIT don’t need to restrict their diet or stop taking medications.

Source: CBC news


Woman’s IVF Prevented Fatal Brain Disorder in Her Children

A woman whose genes put her at high risk for a rare brain disorder was able to avoid passing on the condition to her children through a special in-vitro fertilization (IVF) procedure, according to a new report of the case.

The woman, a 27-year-old in the United States, had undergone genetic testing that showed she had inherited a gene that put her at risk for Gerstmann-Straussler-Scheinker (GSS) syndrome, a rare and fatal brain disorder seen in only a few families in the world. Symptoms of the condition usually appear between ages 35 and 55, and include progressively worsening speech, movement and memory problems.

To have children, the woman and her husband used IVF, an assisted-reproduction technique in which eggs from the mother are fertilized in a laboratory. But before implanting the embryos in the uterus, doctors took an extra step and screened the embryos for the GSS genetic mutation.

Source: Live science


Ghost white baby’ born without most of her blood

Hope Juarez’s first name is an appropriate one: The 6-week-old is only the second known “ghost white baby” born in recent years to actually survive. She’s so described because she was born with almost no blood, giving her a very white appearance.

The medical miracle, which began three weeks before 27-year-old Jennifer Juarez’s due date, when she realized the regular kicking she’d been feeling had ceased.

She went to her midwife, who asked the Fountain Valley, Calif., woman what her gut feeling was. “Something’s not right,” Juarez replied. And it wasn’t. While some fetal blood loss happens in all but 2 percent of pregnancies, Hope had suffered a fetal-maternal hemorrhage, and doctors estimate she lost around 80 percent of her blood.

An emergency C-section allowed Hope to get a life-saving blood transfusion. Why fetal-maternal hemorrhages occur remains largely a mystery; “a lot of it just happens spontaneously,” says a neonatologist at Kaiser Permanente, Irvine Medical Center, where Hope was born.

What is clear is that Juarez’s quick reaction saved her daughter’s life; doctors say Hope could have died had she spent just a few more hours in the womb.

on 2012 a 6-month-old who was the other baby to recently survive a similar complication. Olivia Bearman’s mother also noticed the baby had stopped kicking.

After birth it was discovered the child had “lost blood directly into her mum’s blood circulation,” explains a neonatal nurse.

Source: Fox news


Neurons in spinal cord send Cc of commands back to brain

Research group led by Professor Silvia Arber at the University of Basel’s Biozentrum and the Friedrich Miescher Institute for Biomedical Research has now discovered, that many neurons in the spinal cord send their instructions not only towards the musculature, but at the same time also back to the brain via an exquisitely organized network.
This dual information stream provides the neural basis for accurate control of arm and hand movements.

Movements of our arms and hands, in particular, call for extremely precise coordination.
The brain sends a constant stream of commands via the spinal cord to our muscles to execute a wide variety of movements.

This stream of information from the brain reaches interneurons in the spinal cord, which then transmit the commands via further circuits to motor neurons innervating muscles.

The research group led by Silvia Arber at the Biozentrum of the University of Basel and the Friedrich Miescher Institute for Biomedical Research has now elucidated the organization of a second information pathway taken by these commands.
The scientists showed that many interneurons in the mouse spinal cord not only transmit their signals via motor neurons to the target muscle, but also simultaneously send a copy of this information back to the brain.

“The motor command to the muscle is sent in two different directions – in one direction, to trigger the desired muscular contraction and in the other, to inform the brain that the command has actually been passed on to the musculature,” Chiara Pivetta, first author of the publication, said.

In analogy to e mail transmission, the information is thus not only sent to the recipient but also to the original requester.
What happens to the information sent by spinal interneurons to the brain? As Arber’s group discovered, this input is segregated by function and spatially organized within a brainstem nucleus.

Information from different types of interneurons thus flows to different areas of the nucleus. For example, spinal information that will influence left-right coordination of a movement is collected at a different site than information affecting the speed of a movement.

The findings are published in the journal Cell.

Source: Yahoo news


Drivers With ADHD: Higher Risk for Crashes?

Drivers with attention-deficit/hyperactivity disorder (ADHD) are nearly 50 percent more likely to be in a serious car crash, a new study suggests.

Further, men with ADHD can dramatically decrease their risk of traffic accidents if they take medication for their condition, the Swedish researchers said.

“This study confirms the importance of treatment and medication for adults with ADHD as well as teens,” said Ruth Hughes, CEO of Children and Adults With Attention-Deficit/Hyperactivity Disorder, a patient advocacy group.

“The core symptoms of ADHD include problems with sustained attention and impulsivity, which can have an adverse effect on driving safely,” said Hughes, who was not involved in the new study. “All drivers with ADHD need to responsibly manage their treatment to reduce driving risks.”

The new findings come from a review of more than 17,000 people in Sweden with ADHD, aged 18 to 46. Researcher Henrik Larsson and colleagues at the Karolinska Institute used databases to track whether the patients had been in a car accident between 2006 and 2009, and if they had a prescription for ADHD medication at the time.

Overall, having ADHD increased a man’s risk of a traffic crash by 47 percent and a woman’s risk by 45 percent, the researchers found.

They then investigated the role of medication in preventing crashes by determining whether people involved in a wreck had filled a prescription for ADHD medicine within the previous six months.

Dr. Lenard Adler, a professor of psychiatry at NYU Langone Medical Center in New York City, said despite a broad definition of taking medication, “men [who were] treated substantially lowered their risk for accidents.”

Access to ADHD medication reduced men’s risk of a car wreck by 58 percent compared to men who did not take medication, according to the study. Women with ADHD, however, did not receive any significant benefit from medication in terms of car crashes.

The study, published online Jan. 29 in the journal JAMA Psychiatry, did not receive any funding from drug companies.

Breaking down the numbers further, the researchers estimated that between 41 percent and 49 percent of the car accidents involving men with ADHD could have been avoided if they had been taking their medication as prescribed.

About three out of five children with ADHD carry the disorder with them into adulthood, according to the Anxiety and Depression Association of America. That amounts to about 8 million adults living with ADHD.

Previous research with ADHD patients in virtual-reality driving simulators found that they are more likely to speed, drive erratically, tap the breaks and accelerate into potential accidents, said Adler, who did not take part in the Swedish research.

Source: Web md


Oral insulin capsule trial a success, company says

Israel’s Oramed, which is racing Novo Nordisk of Denmark to develop the world’s first insulin pill, moved a step closer to its goal on Thursday by announcing successful results from a small mid-stage test.

The oral drug delivery specialist said its insulin capsule had met all primary and secondary endpoints in a Phase IIa clinical trial and it now plans to launch a larger mid-stage study in the third quarter.

Shares in the Nasdaq-listed company opened 10 percent higher at $28.50 on the news. The stock has surged from around $4 since the end of 2012 on rising hopes for its insulin pill.

The concept of oral insulin as a way to relieve diabetics of several daily injections has been around since the 1930s, but making it a reality is extremely difficult because insulin is destroyed by enzymes in the digestive system.

Oramed believes that it has now found a solution to allow enough insulin to survive the onslaught of digestive juices to still do some good.

At least 90 percent of the more than 382 million diabetes sufferers worldwide are in the type 2 category, according to the International Diabetes Foundation, which expects the number of diabetes patients to near 600 million by 2035.

Consensus analyst forecasts suggest that the overall diabetes drug market, worth $37 billion a year at present, will reach more than $57 billion by 2018, according to Thomson Reuters Pharma.

Oral insulin could make it easier for sufferers to start early treatment, slow progression of the disease and delay the need for injections, Oramed said. Unlike injections, the ingested form passes first into the liver, which regulates the secretion of insulin into the bloodstream.

The new year-long Phase IIb study in the United States will study 150 type 2 diabetes patients and mainly test for the drug’s effectiveness, Chief Executive Nadav Kidron told Reuters after the company issued results of the Phase IIa trial.

During the Phase IIa trial, conducted under a new U.S. Food and Drug Administration (FDA) drug protocol, 30 patients with type 2 diabetes entered an in-patient setting for one week.

“The FDA wanted us to show one thing – that it was safe so they will let us do a IIb trial,” Kidron said.

While Oramed was not checking for efficacy, Kidron said the IIa trial revealed that it was effective, though the sample size was too small for FDA purposes.

Oramed will also need to conduct a final large-scale Phase III trial before the drug is licensed for sale, so the capsule is still years away from hitting the market.

The company is, however, ahead of Novo Nordisk, which has yet to start Phase II testing.

Oramed is hoping to partner with large pharmaceutical firms for development and sales of the drug. But Kidron said that only preliminary discussions have taken place so far.

The company also plans to initiate a Phase IIa FDA study for type 1 diabetes in the near term.

The global expense for diabetes is about $500 billion and an oral version could bring a large drop in costs.

Oramed noted that the pill would not eliminate the eventual need for injections but could delay the shift to needles by many years.

Source: Yahoo news


Study confirms ‘he hormone’ link to heart attacks

Heavily promoted male hormone products may be sending men flocking to stores, but their next stop may be the emergency room, according to a new study published Wednesday.

The research confirms earlier studies that show men with heart disease double their risk of heart attack soon after they start using testosterone gels or other supplements. And testosterone doubled the risk in men over 65 with or without heart disease.

“Patients and their physicians should discuss the risk of heart attacks when considering testosterone therapy,” said Sander Greenland, a professor of epidemiology at the UCLA Fielding School of Public Health, who led the study.

It’s a similar pattern to women using hormone replacement therapy after menopause — doctors used to think it lowered the risk of heart attacks and cancer, but it in fact has the opposite effect.

The study, published in the Public Library of Science journal PLoS ONE, confirms the results of several smaller studies. One published in November found that the use of “low T” therapy boosted the risk of serious problems including heart attack, stroke and death in men who already had heart trouble and who had low testosterone.

And another one released in December found that men with higher levels of the male hormone are more likely to have weak or no response to a flu vaccine, meaning that their bodies don’t mount a strong defense.

Nonetheless, the testosterone products are very heavily marketed to older men. And an influential essay in the New York Times Magazine, titled “The He Hormone,” brought even more attention to the idea of “man-opause”.

Greenland’s team, along with experts at the National Cancer Institute and Consolidated Research, Inc., looked at the records of more than 55,000 men. Heart attack rates more than doubled in men over 65 in the 90 days after getting a testosterone prescription, and it more than tripled for men 75 or older.

To be sure, they compared the men getting testosterone to those getting prescriptions for erectile dysfunction drugs, as the two groups are similar in many ways. The ED drugs, which include brands such as Viagra and Cialis, only very slightly raised the risk of heart attack.

“Taken together, the evidence supports an association between testosterone therapy and risk of serious, adverse cardiovascular-related events — including non-fatal myocardial infarction (heart attack) — in men,” they concluded.

Source: NBC news


Peanut allergy treatment ‘a success’

Doctors say a potential treatment for peanut allergy has transformed the lives of children taking part in a large clinical trial.

The 85 children had to eat peanut protein every day – initially in small doses, but ramped up during the study.

The findings, published in the Lancet, suggest 84% of allergic children could eat the equivalent of five peanuts a day after six months.

Experts have warned that the therapy is not yet ready for widespread use.

Peanuts are the most common cause of fatal allergic reactions to food.

There is no treatment so the only option for patients is to avoid them completely, leading to a lifetime of checking every food label before a meal.

The trial, at Addenbrooke’s Hospital in Cambridge, tried to train the children’s immune systems to tolerate peanut protein.

Every day they were given a peanut protein powder – starting off on a dose equivalent to one 70th of a peanut.

The theory was that patients started at the extremely low dose, well below the threshold for an allergic response.

Once a fortnight the dose was increased while the children were in hospital, in case there was an reaction, and then they continued taking the higher dose at home.

The majority of patients learned to tolerate the peanut.

Lena Barden, 11, from Histon in Cambridgeshire, said: “It meant a trip to the hospital every two weeks.

“A year later I could eat five whole peanuts with no reaction at all.

“The trial has been an experience and adventure that has changed my life and I’ve had so much fun, but I still hate peanuts!”

‘Dramatic transformation’
One of the researchers, Dr Andrew Clark, told the BBC: “It really transformed their lives dramatically; this really comes across during the trial.

“It’s a potential treatment and the next step is to make it available to patients, but there will be significant costs in providing the treatment – in the specialist centres and staff and producing the peanut to a sufficiently high standard.”

Fellow researcher Dr Pamela Ewan added: “This large study is the first of its kind in the world to have had such a positive outcome, and is an important advance in peanut allergy research.”

But she said further studies would be needed and that people should not try this on their own as this “should only be done by medical professionals in specialist settings”.

The research has been broadly welcomed by other researchers in the field, but some concerns about how any therapy could be introduced have been raised.

Caution
Prof Gideon Lack, who is running a peanut allergy trial at the Evelina Children’s Hospital in London, told the BBC: “This is a really important research step in trying to improve our management of peanut allergy, but is not yet ready for use in clinical practice.

“We need a proper risk assessment needs to be done to ensure we will not make life more dangerous for these children.

He warned that 60% of people with a peanut allergy were also allergic to other nuts so a carefree lifestyle would rarely be an option.

Prof Barry Kay, from the department of allergy and clinical immunology at Imperial College London, said: “The real issues that still remain include how long the results will last, and whether the positive effects might lead affected individuals to have a false sense of security.

“Another issue to address is whether there will be long term side-effects of repeated peanut exposure even where full allergic reaction does not occur, such as inflammation of the oesophagus.

“So, this study shows encouraging results that add to the current literature, but more studies are needed to pin down these issues before the current advice to peanut allergy sufferers, which is to avoid eating peanuts, is changed.”

Maureen Jenkins, director of clinical services at Allergy UK, said: “The fantastic results of this study exceed expectation.

“Peanut allergy is a particularly frightening food allergy, causing constant anxiety of a reaction from peanut traces.

Source: BBC news


New method makes stem cells in about 30 minutes, scientists report

In a feat that experts say is a significant advance for regenerative medicine, scientists have discovered a surprisingly simple method for creating personalized stem cells that doesn’t involve human embryos or tinkering with DNA.

Two studies published Wednesday in the journal Nature describe a novel procedure for “reprogramming” the blood cells of newborn mice by soaking the cells in a mildly acidic solution for 30 minutes. This near-fatal shock caused the cells to become pluripotent, or capable of growing into any type of cell in the body.

When the reprogrammed cells were tagged and injected into a developing mouse, they multiplied and grew into heart, bone, brain and other organs, the scientists found.
“It was really surprising to see that such a remarkable transformation could be triggered simply by stimuli from outside of the cell,” said lead study author Haruko Obokata, a biochemistry researcher at the RIKEN research institute in Japan. “Very surprising.”

The simplicity of the technique, which Obokata and her colleagues dubbed stimulus triggered acquisition of pluripotency, or STAP, caught many experts off-guard.
“So you mistreat cells under the right conditions and they assume a different state of differentiation? It’s remarkable,” said Rudolf Jaenisch, a pioneering stem cell researcher at MIT who was not involved in the study. “Let’s see whether it works in human cells, and there’s no reason why it shouldn’t.”

Obokata said that researchers had already begun experiments on human cells, but offered no details.

Due to their Zelig-like ability to form any number of specialized cells, pluripotent stem cells are considered the basic building blocks of biology. Scientists are working on ways to use them to repair severed spinal cords, replace diseased organs, and treat conditions as varied as diabetes, blindness and muscular dystrophy.

By using stem cells spawned from the patient’s own cells, replacement tissues would stand less of a chance of being attacked by the patient’s own immune system, researchers say. That would spare patients the need to undergo a lifetime regimen of dangerous, immune-suppressing drugs.

But progress toward these lofty goals has been slow, due in part to the challenges of current stem cell production methods. The practice of harvesting stem cells from human embryos makes many people uncomfortable, and some religious groups have pressed for limits or bans on their use. Even scientists who want to study them say they may not be practical for medical therapies because they could be rejected by a patient’s body.

Another approach is to rewind a patient’s own mature cells to a pluripotent state. Dr. Shinya Yamanaka, the first person to make these induced pluripotent stem cells, won a Nobel Prize for this work in 2012. However, the reprogramming process converts only about 1% of the cells into iPS cells, and questions remain about their long-term stability and safety.

The STAP method presents a simpler, cheaper and faster method of producing stem cells, said Chris Mason, a professor of regenerative medicine bioprocessing at University College London.

“How much easier can it possibly get,” Mason told the Science Media Centre, an English organization that promotes scientific understanding on controversial subjects.
“If it works in man, this could be the game changer that ultimately makes a wide range of cell therapies available using the patient’s own cells as starting material,” he said. “The age of personalized medicine would have finally arrived.”

The STAP approach was inspired by observations of plant cells that changed character when they were exposed to environmental stress, according to the research team from RIKEN and Harvard’s Brigham and Women’s Hospital in Boston.

Obokata and her colleagues set about “stressing” mouse blood cells in a variety of ways to see if they would change. They exposed them to heat, deprived them of nutrition and repeatedly poured them through narrow glass pipes.

The method they ultimately published involved placing the cells in an acid solution for 30 minutes and then spinning them in a centrifuge for five minutes. The process converted 7% to 9% of the original cells into STAP cells, Obokata said.

To see whether the cells had been reprogrammed, researchers engineered the mice with a gene that would cause their cells to glow a fluorescent green under ultraviolet light if they became pluripotent. After torturing the blood cells, they began to glow after three days and appeared to peak at seven days, suggesting that they had become pluripotent in just a week’s time. The researchers bolstered the cells’ ability to proliferate by treating them with hormones and an immune cell secretion called leukemia inhibitory factor.

To fully prove that they had become pluripotent, the STAP cells were injected into normal mouse embryos. The resulting offspring, called a chimera, were a mix of regular cells and glowing STAP cells.

Andrew McMahon, director of USC’s Eli and Edyth Broad Center for Regenerative Medicine, said the creation of a chimera was critical to proving that blood cells had changed in a fundamental way.

“That’s the most rigorous [test] you could possibly do,” said McMahon, who was not involved in the study. It shows that the STAP cells can make every type of cell in the embryo and that they “can organize in a normal-looking way, so that what comes out is a normal looking fetus.”

McMahon said the study was also surprising in that it showed that mature cells could be reprogrammed without having to divide.

“That’s why the change is so rapid, because the cells don’t have to undergo division for this to occur,” he said. “It’s a really interesting and novel finding.”

Yamanaka, who was not involved in the STAP study, said the research would undoubtedly help scientists understand the basic biology of cellular reprogramming.

“The findings are important,” said Yamanaka, who directs Kyoto University’s Center for iPS Cell Research.

The reasons why stress causes cells to drastically alter their function remains a mystery, Obokata and her colleagues said.

She declined to say whether the researchers were seeking a patent on the STAP procedure.

Source: latimes